Aplastic anemia classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 32: Line 32:
|<1.0 G / L
|<1.0 G / L
|<0.5G/L
|<0.5G/L
|0.2G/l
|0.2G/L
|}
|}
This classification is of prognostic relevance and has an influence on therapeutic procedures.
This classification is of prognostic relevance and has an influence on therapeutic procedures.
Line 38: Line 38:
{| class="wikitable"
{| class="wikitable"
|+classification  based on the presumed etiology
|+classification  based on the presumed etiology
!''Acquired''
!''Acquired aplastic anemia''  
!
!
|-
|-
Line 46: Line 46:
|Secondry                 
|Secondry                 
|Irradiation                                                                                         
|Irradiation                                                                                         
Drugs
Drugs and chemicals: cytotoxic agents, benzene, chloromphenicol, gold
 
salts, NSAIDS


Idiosyncratic reactions
Idiosyncratic reactions


Viruses
Viruses: Epstein Barr virus, parvovirus B19, HIV


Immune diseases
Immune diseases
Line 58: Line 60:
PNH
PNH
|-
|-
|'''''Inherited'''''
|'''''Inherited aplastic anemia'''''
|Fanconis anemia
|Fanconis anemia
Dyskeratosis congenital
Dyskeratosis congenital

Revision as of 19:41, 14 August 2018

Aplastic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Aplastic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Aplastic anemia classification On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Aplastic anemia classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Aplastic anemia classification

CDC on Aplastic anemia classification

Aplastic anemia classification in the news

Blogs on Aplastic anemia classification

Directions to Hospitals Treating Aplastic anemia

Risk calculators and risk factors for Aplastic anemia classification


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2] Nazia Fuad M.D.

Overview

Aplastic anemia can be classified into mild, moderate, severe, and very severe depending on the severity of cellularity of bone marrow and the blood tests.

Classification

Aplastic anemia may be classified according to blood cell counts into 3 subgroups:[1]

    • Moderately severe aplastic anemia or non severe AA (nSAA)
    • Severe aplastic anemia (SAA)
    • Very severe aplastic anemia(vSAA)
Classification of aplastic anemia (two out of three criteria must be met)
nSAA SAA vSAA
Reticulocytes <20G/L <20G/L <20G/L
Platelets <50 G / L <20G/L <20G/L
Neutrophilic granulocytes <1.0 G / L <0.5G/L 0.2G/L

This classification is of prognostic relevance and has an influence on therapeutic procedures.

classification based on the presumed etiology
Acquired aplastic anemia
Idiopathic
Secondry Irradiation

Drugs and chemicals: cytotoxic agents, benzene, chloromphenicol, gold

salts, NSAIDS

Idiosyncratic reactions

Viruses: Epstein Barr virus, parvovirus B19, HIV

Immune diseases

Pregnancy

PNH

Inherited aplastic anemia Fanconis anemia

Dyskeratosis congenital

Amegakaryocytic thrombocytopenia

Shwachman-Diamond syndrome

References

  1. Dolberg OJ, Levy Y (2014). "Idiopathic aplastic anemia: diagnosis and classification". Autoimmun Rev. 13 (4–5): 569–73. doi:10.1016/j.autrev.2014.01.014. PMID 24424170.